| Species Reactivity | Human |
| Clone | 13H10 |
| Source/Isotype | Mouse IgG2a,Kappa |
| Application | / |
| Specificity | Detects ITGB4 |
| Gene | ITGB4 |
| Other Names | CD104, GP150, JEB5A, JEB5B |
| Gene ID | 3691 (Human) |
| Background | The ITGB4 gene, located in region 25(17q25) of the long arm of human chromosome 17, encodes an integrin Β4 transmembrane glycoprotein, which binds to the α6 subunit to form the laminin receptor complex, which is responsible for the formation of the laminin receptor complex, through the regulation of FAK/SRC, EGFR-AKT, MEK/ERK/C-jun and other signaling pathways involved in cell adhesion, polarity maintenance and tumor biological processes. Its mutations are directly related to epidermolysis bullosa with pyloric atresia (Jeb-pa) , nonsense variants lead to lethal phenotypes, missense variants are mostly found in non-lethal types, and variant hotspots are concentrated in the FNIII and VWFA domains. In the field of tumors, ITGB4 is highly expressed in a variety of solid tumors, such as colorectal cancer, prostate cancer, non-small-cell lung carcinoma, head and neck squamous-cell carcinoma, and pancreatic ductal adenocarcinoma, it is associated with tumor progression, drug resistance (EG, EGFR-AKT pathway resistance in colorectal cancer and PD-1 inhibitor resistance in bladder cancer) and poor prognosis It affects immunotherapy response by activating the MEK/Erk/C-jun pathway to regulate PD-L1 expression, while positively correlated with NECTIN4 to enhance ADC drug sensitivity (such as enfortumab vedotin) , providing new ideas for combination therapy. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Species Reactivity | Human |
| Clone | 13H10 |
| Source/Isotype | Mouse IgG2a,Kappa |
| Application | / |
| Specificity | Detects ITGB4 |
| Gene | ITGB4 |
| Other Names | CD104, GP150, JEB5A, JEB5B |
| Gene ID | 3691 (Human) |
| Background | The ITGB4 gene, located in region 25(17q25) of the long arm of human chromosome 17, encodes an integrin Β4 transmembrane glycoprotein, which binds to the α6 subunit to form the laminin receptor complex, which is responsible for the formation of the laminin receptor complex, through the regulation of FAK/SRC, EGFR-AKT, MEK/ERK/C-jun and other signaling pathways involved in cell adhesion, polarity maintenance and tumor biological processes. Its mutations are directly related to epidermolysis bullosa with pyloric atresia (Jeb-pa) , nonsense variants lead to lethal phenotypes, missense variants are mostly found in non-lethal types, and variant hotspots are concentrated in the FNIII and VWFA domains. In the field of tumors, ITGB4 is highly expressed in a variety of solid tumors, such as colorectal cancer, prostate cancer, non-small-cell lung carcinoma, head and neck squamous-cell carcinoma, and pancreatic ductal adenocarcinoma, it is associated with tumor progression, drug resistance (EG, EGFR-AKT pathway resistance in colorectal cancer and PD-1 inhibitor resistance in bladder cancer) and poor prognosis It affects immunotherapy response by activating the MEK/Erk/C-jun pathway to regulate PD-L1 expression, while positively correlated with NECTIN4 to enhance ADC drug sensitivity (such as enfortumab vedotin) , providing new ideas for combination therapy. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
